Abstract

BOBADILLA-QUESADA, Edna Julieth et al. Use of Glucocorticoids in Duchenne Muscular Dystrophy Patients. Rev. Cienc. Salud [online]. 2025, vol.23, n.spe, e23e11.  Epub Apr 22, 2025. ISSN 1692-7273.  https://doi.org/10.12804/revistas.urosario.edu.co/revsalud/a.13612.

Duchenne muscular dystrophy is a severe and debilitating condition that leads to difficulties in gait, and movement and eventually to the need for mechanical ventilation and premature death. However, its natural history has evolved hand in hand with the emergence of new interventions, that have been shown to have a positive effect on the disease. Glucocorticoid drug therapy is one of the standards of care in patients with Duchenne muscular dystrophy; its effects are related to prolongation of gait loss time, less decrease in functional test scores, and preservation of hand-mouth function and hand function for grasping objects. The benefit of glucocorticoid use is established in patients with and without ambulation by having an impact on pulmonary function. However, it is important to be clear about the side effects of treatment. The present paper aims to provide a synthesis on the appropriate use of glucocorticoids and follow-up therapy in patients with Duchenne muscular dystrophy.

Keywords : Duchenne muscular dystrophy; glucocorticoids: therapeutics.

        · abstract in Spanish | Portuguese     · text in Spanish     · Spanish ( pdf )